180 related articles for article (PubMed ID: 33360173)
1. Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®).
Hauser RA; Zeitlin L; Fisher S; D'Souza R
Parkinsonism Relat Disord; 2021 Jan; 82():133-137. PubMed ID: 33360173
[TBL] [Abstract][Full Text] [Related]
2. Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.
LeWitt PA; Verhagen Metman L; Rubens R; Khanna S; Kell S; Gupta S
Clin Neuropharmacol; 2018; 41(2):47-55. PubMed ID: 29432286
[TBL] [Abstract][Full Text] [Related]
3. Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia.
Hauser RA; Zeitlin L; Fisher S; D'Souza R
J Parkinsons Dis; 2020; 10(3):915-925. PubMed ID: 32568108
[TBL] [Abstract][Full Text] [Related]
4. Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules.
Modi NB; Mittur A; Rubens R; Khanna S; Gupta S
Clin Neuropharmacol; 2019; 42(1):4-8. PubMed ID: 30520758
[TBL] [Abstract][Full Text] [Related]
5. Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
Nausieda PA; Hsu A; Elmer L; Gil RA; Spiegel J; Singer C; Khanna S; Rubens R; Kell S; Modi NB; Gupta S
J Parkinsons Dis; 2015; 5(4):837-45. PubMed ID: 26444090
[TBL] [Abstract][Full Text] [Related]
6. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
Tetrud J; Nausieda P; Kreitzman D; Liang GS; Nieves A; Duker AP; Hauser RA; Farbman ES; Ellenbogen A; Hsu A; Kell S; Khanna S; Rubens R; Gupta S
J Neurol Sci; 2017 Feb; 373():116-123. PubMed ID: 28131167
[TBL] [Abstract][Full Text] [Related]
7. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
8. Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease.
Silver DE; Trosch RM
Neurology; 2016 Apr; 86(14 Suppl 1):S25-35. PubMed ID: 27044647
[TBL] [Abstract][Full Text] [Related]
9. Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease.
Greig SL; McKeage K
CNS Drugs; 2016 Jan; 30(1):79-90. PubMed ID: 26692288
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)).
Hsu A; Yao HM; Gupta S; Modi NB
J Clin Pharmacol; 2015 Sep; 55(9):995-1003. PubMed ID: 25855267
[TBL] [Abstract][Full Text] [Related]
11. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
Hauser RA; Hsu A; Kell S; Espay AJ; Sethi K; Stacy M; Ondo W; O'Connell M; Gupta S;
Lancet Neurol; 2013 Apr; 12(4):346-56. PubMed ID: 23485610
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations.
Modi NB; Mittur A; Dinh P; Rubens R; Gupta S
Clin Neuropharmacol; 2019; 42(5):149-156. PubMed ID: 31306216
[TBL] [Abstract][Full Text] [Related]
13. Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
Kestenbaum M; Fahn S
Expert Opin Drug Saf; 2015 May; 14(5):761-7. PubMed ID: 25697185
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill
LeWitt PA; Giladi N; Navon N
Parkinsonism Relat Disord; 2019 Aug; 65():131-138. PubMed ID: 31176632
[TBL] [Abstract][Full Text] [Related]
15. Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson's disease.
Hauser RA; Ellenbogen A; Khanna S; Gupta S; Modi NB
Neuropsychiatr Dis Treat; 2018; 14():839-845. PubMed ID: 29606877
[TBL] [Abstract][Full Text] [Related]
16. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Rytary
Mittur A; Gupta S; Modi NB
Clin Pharmacokinet; 2017 Sep; 56(9):999-1014. PubMed ID: 28236251
[TBL] [Abstract][Full Text] [Related]
18. Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson's Disease: Clinical Trial Post Hoc Analyses.
Pahwa R; Aldred J; Gupta N; Terasawa E; Garcia-Horton V; Steffen DR; Kandukuri PL; Chaudhari VS; Jalundhwala YJ; Bao Y; Kukreja P; Isaacson SH
Neurol Ther; 2022 Jun; 11(2):711-723. PubMed ID: 35192177
[TBL] [Abstract][Full Text] [Related]
19. The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.
Huang X; Lewis MM; Van Scoy LJ; De Jesus S; Eslinger PJ; Arnold AC; Miller AJ; Fernandez-Mendoza J; Snyder B; Harrington W; Kong L; Wang X; Sun D; Delnomdedieu M; Duvvuri S; Mahoney SE; Gray DL; Mailman RB
J Parkinsons Dis; 2020; 10(4):1515-1527. PubMed ID: 32986682
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.
Mao Z; Hsu A; Gupta S; Modi NB
J Clin Pharmacol; 2013 May; 53(5):523-31. PubMed ID: 23426902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
